U.S. Markets open in 7 hrs 33 mins

Adynxx, Inc. (ADYX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4000-0.0019 (-0.47%)
At close: 11:19AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4019
Open0.4300
Bid0.0000 x 800
Ask0.0000 x 1300
Day's Range0.4000 - 0.4300
52 Week Range0.3100 - 2.8900
Volume2,961
Avg. Volume1,336
Market Cap2.323M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.8190
Earnings DateNov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 06, 2019
1y Target Est2.80
  • GlobeNewswire

    Adynxx Reports Third Quarter 2019 Financial Results

    SAN FRANCISCO, Nov. 14, 2019 -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and.

  • GlobeNewswire

    Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic

    Adynxx, Inc. (ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced the receipt of a Notice of Award for $602,516 from the National Institute on Neurological Disease and Stroke (NINDS), part of the National Institutes of Health (NIH), to support development of AYX2, the company’s product candidate intended to treat chronic pain. As previously announced, in December 2018 Adynxx received an award from the National Institute on Drug Abuse (NIDA), part of the NIH, for up to $15 million to support clinical development of its lead program, brivoligide, which is being studied in Phase 2 clinical trials for postoperative pain.

  • GlobeNewswire

    Adynxx Reports Second Quarter 2019 Financial Results

    SAN FRANCISCO, Aug. 14, 2019 -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and.